According to the present status and the experiences obtained during the previous one and a half year, Hungary will get free of PRRS by 2020.
The Porcine Reproductive and Respiratory Syndrome (PRRS) is an economically significant disease that affects the pig industry globally. This section reviews the latest new features on this disease.
The great genetic diversity of East European strains has practical implications, the sensitivity of some of the diagnostic PCR methods can be compromised and the efficacy of the current PRRSV vaccines against the East European genetic variants still needs to be elucidated.
A definitive diagnostic evaluation of PRRS with respect to clinical disease requires that serological information be interpreted in combination with results from other virus assays.
PCR is expensive relative to other diagnostic methods.It should be kept in mind that a positive result on PCR indicates the presence of viral RNA and does not necessarily indicate the presence of infectious PRRSV.
Any tentative clinical diagnosis then should be confirmed by detection of PRRSV (infectious virus, viral antigens and/or viral genomic material) in affected pigs using laboratory methods in conjunction with typical lesions.
The cost of PRRS ranges from €17 to €185/sow/year in the three studies presented.
From 2000 to 2007 a PRRSv eradication plan was developed successfully in Chile. in October 2013 the spread of a new PRRS virus to several important Chilean pig companies was confirmed.